Shot medicine (dupilumab) for severe, unexplained chronic itching
Treatments studied
Part of Skin clinical trials.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 to 90) and can sign consent.
- Your itching has lasted at least 6 months and has no clear cause found by the study doctor.
- Your itching affects at least two areas: legs, arms, or your trunk (torso).
- Your itching is very severe: your worst itch is 7 or higher (out of 10) and you rate your itch as “severe.”
- You’ve already tried other treatments but they didn’t control your itching well.
- You are not currently on dupilumab (study drug or commercial), and you don’t have conditions that block safe use (like serious infections, HIV, or certain cancer histories).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special light treatment (photobiomodulation) to see if it can safely reduce itch. It compares the treated area to a similar untreated area on your body.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.